Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Guggenheim Upgrades Health Catalyst to Buy, Announces $14 Price Target

Author: Benzinga Newsdesk | January 26, 2024 06:31am
Guggenheim analyst Jack Wallace upgrades Health Catalyst (NASDAQ:HCAT) from Neutral to Buy and announces $14 price target.

Posted In: HCAT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist